Across TCGA pan-cancer cohorts, RAB42 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB42 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB42 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB42 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where RAB42 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.267	0.660	.008	24	view →
CCRCC	DFS	Median	II,III,IV	0.454	0.770	.007	21	view →
LUAD	DFS	Median	All	0.531	0.891	.014	4	view →
LSCC	DFS	Median	All	0.958	0.918	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RAB42 tumor-vs-normal RNA expression · all RAB42 data types